ACUTE MYELOID LEUKEMIA

This study tests whether an oral maintenance drug (azacitidine) can help prevent relapse in adults with acute myeloid leukemia (AML) who are in remission but cannot receive a stem cell transplant due to racial or socioeconomic disparities. About 12 participants will take the drug…

This early-phase trial tests whether specially trained natural killer (NK) cells can safely prevent blood cancers like leukemia from coming back after a stem cell transplant. About 15 adults with high-risk disease will receive an infusion of these cells plus a supportive drug. Th…

This study is for people with acute myeloid leukemia (AML) that has come back or not improved with standard treatments. It tests a combination of three or four oral drugs designed to block cancer growth from different angles. The goal is to see if this mix is safe and can help co…

This early-stage trial tests a cell therapy called Orca-T combined with standard drugs to prevent graft-versus-host disease (GVHD) in people with advanced blood cancers who receive a stem cell transplant from a partially matched donor. The main goal is to see if this approach red…

This early-phase trial tests whether combining tagraxofusp (a targeted therapy) with azacitidine (a chemotherapy-like drug) can safely prevent acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) from coming back after a donor stem cell transplant. About 43 adults aged …

This study tests the safety and effectiveness of ponatinib in children aged 1 to under 18 with advanced leukemias, lymphomas, or solid tumors that have come back or not responded to other treatments. The goal is to see if the drug can shrink or control the cancer. About 70 childr…

This early-stage trial tests a pill called olutasidenib in people with certain blood cancers (AML, MDS, or CMML) who have an IDH1 gene change. The goal is to see if taking this drug after a donor stem cell transplant is safe and can help prevent the cancer from coming back. About…

This early-phase trial tests a combination of three drugs—pembrolizumab, decitabine, and venetoclax—in adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or not responded to prior treatment. The goal is to find the safest dose and see how well the dr…

This study tests a drug called DASATINIB in adults with acute myeloid leukemia (AML) that did not improve after standard treatment with VENETOCLAX and AZACITIDINE. The goal is to see if DASATINIB alone can shrink or control the cancer. Participants take the drug for up to 3 month…

This study tests a personalized vaccine made from a patient's own leukemia cells to help prevent the cancer from coming back. It is for adults with acute myeloid leukemia who are in remission after initial chemotherapy. The vaccine is designed to train the immune system to recogn…

This study watches adults in Korea with newly diagnosed acute myeloid leukemia (AML) who are receiving the drug Mylotarg. Researchers will track side effects and how the disease responds to treatment. The goal is to better understand the drug's safety and effectiveness in real-wo…

This study tests a combination of interferon-γ and donor immune cells for people whose acute myeloid leukemia or myelodysplastic syndromes have returned after a stem cell transplant. The goal is to see if this treatment can control the disease and improve survival. About 45 adult…

This study tests a combination of three drugs (olutasidenib, venetoclax, and azacitidine) in people with a specific genetic subtype of acute myeloid leukemia (IDH1-mutated). The goal is to see if this combo works as well as or better than standard chemotherapy, with fewer side ef…

This study tests whether adding two targeted drugs, midostaurin and gemtuzumab ozogamicin, to standard chemotherapy can improve outcomes for adults newly diagnosed with acute myeloid leukemia (AML) who have certain genetic changes. The trial has two phases: first to find the safe…

This early-stage study tests a new treatment called SC-DARIC33 for children and young adults up to age 30 whose acute myeloid leukemia (AML) has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are genetically modified to be…

This study tests a combination of two or three drugs (ivosidenib, venetoclax, with or without azacitidine) in people with certain blood cancers that have an IDH1 mutation. The goal is to find the best dose and see how well the drugs control the cancer. About 96 adults with acute …

This study tests whether adding the drug venetoclax to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia or a related high-risk blood condition live longer without their cancer returning. About 650 participants aged 18 to 75 will receive either veneto…

This early-phase study tests adding the drug venetoclax to standard chemotherapy for adults newly diagnosed with acute myeloid leukemia (AML) or advanced myelodysplastic syndrome (MDS). The goal is to find the safest dose and see if the combination works better than chemo alone. …

This early-phase trial tests a new type of CAR T cell therapy that can be given to any patient with CD7-positive blood cancers like T-cell leukemia or lymphoma. The therapy uses specially designed immune cells to target and kill cancer cells. The study will check if the treatment…

This study looks at whether people with acute myeloid leukemia (AML) whose cancer is well-controlled can stop their chemotherapy drugs (azacitidine or decitabine plus venetoclax) for a while without the leukemia coming back. Participants must be in remission with no detectable ca…

This study tests a combination of three drugs (ASTX727, venetoclax, and gilteritinib) for people with acute myeloid leukemia or high-risk myelodysplastic syndrome that has a specific gene change called FLT3. The goal is to find the best dose and see how well the drugs work togeth…

This study tests two different methods to lower the risk of graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body, after a stem cell transplant. The trial includes 120 adults with acute leukemia or myelodysplastic syndrome (MDS) whos…

This study tests a three-drug combination (cladribine, low-dose cytarabine, and venetoclax) in 68 adults aged 16-70 with acute myeloid leukemia that has come back or not responded to prior treatment. The goal is to see if this combo can shrink or eliminate the cancer. Participant…

This early-phase study tests a new treatment called CER-1236 for people with acute myeloid leukemia, myelodysplastic syndrome, or myelofibrosis that has not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recog…

This early-phase trial tests whether adding emapalumab to standard medications can safely prevent graft-versus-host disease (GVHD) in 15 adults with acute myeloid leukemia or myelodysplastic syndrome receiving a reduced-intensity donor stem cell transplant. Emapalumab blocks an i…

This study tests a three-drug combination (chidamide, venetoclax, and azacitidine) in adults with acute myeloid leukemia whose cancer did not respond to the first round of venetoclax and azacitidine. The goal is to see if adding chidamide can improve remission rates. About 32 par…

This study is testing a new drug called BGB-11417 for people with certain blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The drug works by blocking a protein that helps cancer cells survive. The study will find safe doses and see if the drug …

This study tests whether two drugs, venetoclax and revumenib, can control minimal residual disease (MRD) in people with acute myeloid leukemia (AML). MRD means a small number of leukemia cells remain after treatment, even though standard tests show remission. The trial enrolls ab…

This study is for people with certain blood cancers (like leukemia) who are getting a half-matched bone marrow transplant. Researchers are adding a dose of specially grown immune cells (gamma delta T-cells) after the transplant to see if it can kill any leftover cancer cells whil…

This early-phase study tests a new drug called danvatirsen, first alone and then combined with venetoclax, in 38 adults whose acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) have returned or not responded to standard treatments. The goal is to see if the drug is s…

This study tests whether a milder chemotherapy combination (decitabine and venetoclax) given weekly after a bone marrow transplant can help prevent high-risk myeloid cancers like acute myeloid leukemia from coming back. About 20 participants will receive the treatment for up to o…

This study tests a new way to prepare stem cells for transplant in children and adults with blood cancers like leukemia. The method removes certain immune cells to lower the risk of graft-versus-host disease, a serious side effect. About 70 participants will receive the treatment…

This study tests a new treatment for acute myeloid leukemia (AML) that uses a patient's own immune cells, trained to attack the cancer, combined with standard chemotherapy drugs. About 30 adults with AML will receive this therapy to see if it is safe and works. The goal is to imp…

This study tests whether adding the experimental drug APG-2575 (Lisaftoclax) to the standard medicine azacitidine helps older adults with newly diagnosed acute myeloid leukemia (AML) live longer. About 486 participants who cannot have strong chemotherapy will receive either the c…

This study tests a long-acting antibiotic called dalbavancin to prevent serious bloodstream infections in children and young adults with high-risk leukemia who are receiving strong chemotherapy. About 29 participants will receive the drug every 28 days. The goal is to see if it s…

This early-phase trial tests a new therapy using a patient's own immune cells, engineered to target and kill leukemia cells that carry a protein called CD4. The goal is to safely reduce or eliminate remaining cancer in people with AML that has not responded to standard treatments…

This early-phase study tests a new drug called SL-401 combined with standard treatments (azacitidine and venetoclax) in people with certain blood cancers like acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and blastic plasmacytoid dendritic cell neoplasm (BPDCN). T…

This early-phase study tests a new treatment called CD371-YSNVZ-IL18 CAR T cells for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The main goal is to find the safest dose and see what side effects occur. About 15 participants w…

This study is for children whose acute myeloid leukemia (AML) has come back or not responded to treatment. It tests a combination of two oral drugs, venetoclax and ASTX727, to find the best dose and check safety. About 40 children will take part at MD Anderson Cancer Center.

This study compares a new treatment (venetoclax plus the CACAG regimen) to the standard chemotherapy ("3+7") for adults aged 14-75 with newly diagnosed intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if the new combination leads to more complete remiss…

This study looks at the best order of two treatment approaches for older adults with a specific genetic form of acute myeloid leukemia (IDH-mutated AML). Participants will receive either a targeted pill (ivosidenib or enasidenib) first, followed by standard chemotherapy (azacitid…

This study tests a new drug called bleximenib for people with acute leukemia that has come back or not responded to other treatments. The drug targets specific genetic changes in the cancer cells. The study will first find the best dose and then check if it can safely help patien…

This early-phase trial tests a new drug called revumenib alongside standard chemotherapy and a targeted therapy (midostaurin) for adults with a specific genetic form of acute myeloid leukemia (AML). The goal is to find a safe dose that improves remission rates. About 22 newly dia…

This study tests whether a stem cell transplant from a donor can help people with a high-risk type of acute myeloid leukemia (AML) stay cancer-free longer. Participants will receive standard chemotherapy followed by the transplant. The goal is to see if this approach improves sur…

This study tests whether replacing two standard chemotherapy cycles with new drug combinations is safe and effective for children and young adults with acute myeloid leukemia (AML) at intermediate or high risk of relapse. About 36 participants will receive the new cycles and be m…

This study tests a new drug combination (ABC-14) for adults newly diagnosed with acute myeloid leukemia, a type of blood cancer. It compares the new combo to two standard treatments to see if it works better and is safe. About 240 participants will be enrolled to measure remissio…

This early-phase trial tests a combination of CAR T cells designed to attack different targets on leukemia cells in patients with relapsed or hard-to-treat acute myeloid leukemia. About 10 participants aged 6 months and older will receive the therapy to see if it is safe and can …

This study tests whether giving special immune cells (memory-like NK cells) after a stem cell transplant can help control high-risk acute myeloid leukemia (AML) in children and adults. About 68 participants will receive donor stem cells followed by these NK cells. The goal is to …

This early-stage trial tests a drug called SEA-CD70, alone or with standard chemotherapy, in about 178 people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The main goals are to find safe doses and check for side effects. Researchers will also look for sign…

This study looks at whether people with acute myeloid leukemia (AML) who have done well on a combination of venetoclax and azacitidine can safely stop taking these drugs. About 50 participants who have been on treatment for 12 months and are in remission will stop their medicatio…

This study is for older or less-fit adults with a specific type of acute myeloid leukemia (AML) that has a FLT3 mutation. It compares the usual two-drug treatment (azacitidine and venetoclax) to a three-drug combo that adds gilteritinib. The goal is to see if the extra drug helps…

This study tests a new experimental drug called EP0042, alone or with other cancer treatments, in adults with advanced acute myeloid leukemia (AML) or related blood cancers. The main goal is to find a safe dose that might work against the cancer. About 70 people will take part in…

This early-phase study tests the safety of combining two chemotherapy drugs, CPX-351 and gemtuzumab ozogamicin, in adults aged 18-70 with newly diagnosed acute myeloid leukemia. The goal is to find the highest safe dose and see how many patients achieve remission. About 18 partic…

This study tests a low-dose weekly combination of two FDA-approved drugs, decitabine and venetoclax, for people with bone marrow cancers like MDS, AML, and CMML. The goal is to see if this gentler schedule can control the disease while causing fewer treatment delays or interrupti…

This study tests a two-step approach for people with advanced myeloproliferative neoplasms (blood cancers). First, patients receive a chemotherapy drug (decitabine) plus a targeted therapy (ruxolitinib, fedratinib, or pacritinib) to reduce cancer cells. Then, they undergo a donor…

This early-phase study tests the safety of giving special immune cells (CIML NK cells) along with a standard drug (venetoclax) to adults with acute myeloid leukemia (AML) whose disease has come back or is hard to treat. Ten participants will receive the cell infusion after a shor…

This early-phase study tests a new drug called FHD-286 combined with two standard chemotherapy drugs (decitabine and venetoclax) in adults with acute myeloid leukemia (AML) that is hard to treat. The main goal is to find the safest dose and watch for side effects. About 33 people…

This study tests whether giving two drugs (decitabine and filgrastim) after a stem cell transplant can safely prevent leukemia or related blood cancers from coming back in children and young adults. About 37 participants with acute myeloid leukemia, myelodysplastic syndromes, or …

This early-phase study tests a new way to prepare donor stem cells (called Orca-Q) for transplant in people with certain blood cancers like leukemia. The goal is to see if this engineered graft is safe and helps the body accept the new cells without serious side effects. About 30…

This early-stage study tests the safety of a new drug called ziftomenib when combined with standard chemotherapy for people whose acute myeloid leukemia (AML) has returned or not responded to treatment. The study includes adults with specific genetic changes (NPM1 mutation or KMT…

This program provides galinpepimut-S, an experimental immune therapy, to individual patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who have run out of standard treatment options. It is not a clinical trial testing the drug, but a way for patients wit…

This study tests a combination of two drugs—CPX-351 (a liposomal form of standard chemotherapy) and quizartinib—in adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The goal is to find the best dose and see if the combo can control the cancer. …

This study tests whether adding enasidenib to the standard two-drug treatment (ASTX727 and venetoclax) helps more older adults with a specific genetic form of acute myeloid leukemia (IDH2-mutated AML) achieve complete remission. About 93 participants who are newly diagnosed or un…

This study tests a new all-oral combination of three drugs (SNDX-5613, decitabine/cedazuridine, and venetoclax) for people with acute myeloid leukemia (AML) or related leukemia. The goal is to find the best dose and see if it helps control the disease. About 43 participants aged …

This early-phase study tests a new drug called Q702 combined with two standard AML drugs (azacitidine and venetoclax) in 32 adults whose acute myeloid leukemia has returned or not responded to treatment. The main goal is to check the safety of the combination and find the best do…

This study tests a stem cell transplant approach for people with blood cancers like AML and MDS. It uses milder chemotherapy (treosulfan and fludarabine) followed by a donor stem cell infusion, plus drugs to prevent graft-versus-host disease. The goal is to improve survival at 10…

This early-stage trial tests a new antibody drug, GEN3018, in people whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) has returned or stopped responding to treatment. The main goal is to check safety and find the best dose. Up to 78 participants will…

This study tests a combination of two drugs, venetoclax and azacitidine, in about 100 Indian adults newly diagnosed with acute myeloid leukemia (AML) who are not healthy enough for standard intensive chemotherapy. The goal is to see how well the combo controls the cancer and what…

This study tests whether a three-drug combination (ivosidenib, azacitidine, and venetoclax) followed by maintenance therapy with ivosidenib alone can help keep acute myeloid leukemia (AML) with an IDH1 mutation from coming back. It is for people aged 60 and older with newly diagn…

This study tests a combination of three drugs (tagraxofusp, azacitidine, and venetoclax) for people with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) that has returned or progressed after prior treatment. The goal is to see if this combination can help contr…

This study tests a new type of immune cell therapy (CD19-CAR.p40-T) for people with blood cancers like lymphoma and leukemia that have come back or not responded to treatment. About 10 adults will receive their own immune cells that have been modified to better find and attack ca…

This early-stage trial tests whether adding the drug talazoparib to standard chemotherapy is safe for children and young adults up to age 21 whose acute myeloid leukemia has returned or not responded to treatment. The study will find the best dose and watch for side effects. If s…

This early-phase study tests a new drug called rezatapopt combined with azacitidine in 24 adults whose acute myeloid leukemia or myelodysplastic syndrome has a specific TP53 gene mutation (Y220C). The main goal is to check safety and side effects. Participants must have cancer th…

This study tests a combination of three drugs (bugitinib, venetoclax, and cytarabine) in adults with acute myeloid leukemia that has come back or not responded to treatment. The goal is to see if the combo can wipe out hidden cancer cells and keep them away. About 10 participants…

This study tests whether a combination of two drugs (olutasidenib and azacitidine) followed by maintenance therapy can help adults with a specific type of acute myeloid leukemia (IDH1-mutated AML) stay in remission longer. Participants must have already responded to initial treat…

This early-stage study tests a new drug called RPT1G in 24 people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) that have not responded to standard treatments. The main goals are to check if the drug is safe and to find the best dose. This is not …

This study tests adding venetoclax to a standard chemotherapy regimen (CLAG-M) for people with acute myeloid leukemia (AML) or related high-grade blood cancers. The goal is to find the safest dose and see if the combination improves cancer control. About 62 participants will take…

This early-phase trial tests two oral drugs (ziftomenib and quizartinib) together in adults with relapsed or hard-to-treat acute myeloid leukemia (AML). The goal is to find a safe and effective all-pill treatment for common AML subtypes. About 44 participants will be enrolled.

This early-phase study tests whether adding high-dose vitamin C to standard chemotherapy (azacitidine and venetoclax) is safe and effective for adults newly diagnosed with acute myeloid leukemia (AML) who cannot tolerate intensive chemo. About 30 participants will be randomly ass…

This early-phase study tests whether bone marrow from deceased donors can be safely used for people with blood cancers like leukemia and lymphoma. About 12 patients will receive a transplant after chemotherapy, and doctors will monitor for side effects and blood cell recovery for…

This early-stage study is testing a new drug called cirtuvivint, alone or with another drug (ASTX727), in people with blood cancers MDS and AML. The goal is to find the safest dose and see how well it works. About 54 adults whose cancer has returned or not responded to treatment …

This study tests a new combination of drugs (sonrotoclax, azacitidine, and other targeted medicines) in 205 adults with newly diagnosed acute myeloid leukemia. The goal is to see if this mix can achieve complete remission and reduce cancer cells to undetectable levels. Participan…

This study tests whether adding specially prepared donor immune cells can help children recover from stem cell transplants faster and avoid dangerous infections. Participants are children under 25 with high-risk blood cancers who have already received a transplant. The goal is to…

This study tests two different doses of quizartinib as a maintenance therapy for adults with a specific type of acute myeloid leukemia (FLT3-ITD positive) who are in their first complete remission and have not had a stem cell transplant. The goal is to see which dose is safer and…

This study is for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who have received a stem cell transplant from a half-matched donor. After the transplant, participants will receive extra immune cells called natural killer (NK) cells from the same dono…

This study tests three different drug combinations to prevent graft-versus-host disease (GVHD) in 400 people with blood cancers receiving stem cells from unrelated donors. GVHD is a serious complication where donor cells attack the patient's body. The goal is to find which approa…

This study tests a combination of three treatments (PD-1 inhibitor, azacitidine, and low-dose donor lymphocyte infusion) for people whose acute myeloid leukemia has come back after a stem cell transplant. The goal is to see if this approach can control the disease and improve sur…

This study tests a combination of two drugs, enasidenib and azacitidine, in people with a rare, high-risk blood cancer called IDH2-mutant myelodysplastic syndrome. The goal is to see if the treatment can control the disease and reduce side effects. About 63 participants will take…

This study tests whether adding the drug venetoclax to standard chemotherapy helps children and young adults with relapsed acute myeloid leukemia (AML) live longer. About 130 participants aged 29 days to 21 years will be randomly assigned to receive chemotherapy with or without v…

This study tests a two-step, lower-intensity approach using radiation and chemotherapy before a stem cell transplant for people with various blood cancers or disorders. The goal is to see if this gentler preparation reduces the risk of death from the transplant itself. About 63 p…

This early-stage study tests whether adding the experimental drug ziftomenib to standard AML treatments is safe and effective. About 420 adults with specific genetic mutations (NPM1 or KMT2A) will receive one of three drug combinations. The goal is to find the best dose and see i…

This study tests whether adding the drug ruxolitinib to the standard anti-rejection drugs tacrolimus and methotrexate can better prevent graft-versus-host disease (GVHD) in children and young adults (ages 2-22) receiving a bone marrow transplant for blood cancers like leukemia. G…

This study tests whether two newer drugs, CPX-351 and gilteritinib, work better than standard chemotherapy for children and young adults with newly diagnosed acute myeloid leukemia (AML). About 1,186 participants under age 22 will be enrolled. The goal is to improve survival and …

This early-stage study tests a new drug called STX-0712 in people with advanced types of leukemia (CMML or AML) that have not responded to other treatments. The main goals are to find a safe dose and check for side effects. About 105 adults will take part in this first-in-human t…

This study tests whether a drug called dexrazoxane can protect the heart from damage caused by chemotherapy in people with certain blood cancers, like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). About 100 participants will receive dexrazoxane alongs…

This study tests whether adding silibinin (a liver-protecting supplement from milk thistle) to standard chemotherapy can improve outcomes for adults newly diagnosed with a common type of acute myeloid leukemia (non-M3). About 100 participants will receive either standard chemo al…

This early-phase trial tests whether adding natural killer (NK) cells from a healthy donor to the standard drugs azacitidine and venetoclax can help control acute myeloid leukemia (AML). About 32 adults with relapsed or hard-to-treat AML will receive this combination. The main go…

This early-phase study tests whether a daily pill called olutasidenib can safely help adults with a specific type of acute myeloid leukemia (IDH1-mutant AML) stay in remission after standard chemotherapy. About 15 participants will take the drug for at least 4 months while doctor…

This early-phase trial tests a new immune cell therapy (multi-CAR T cells) for people with acute myeloid leukemia that has come back or not responded to treatment. The therapy targets several proteins on leukemia cells to try to destroy them. The study will check safety and how w…

This study tests a new treatment for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. It uses special immune cells, called CIML-NK cells, from a half-matched donor to attack the cancer. The main goal is to see if the infusion is sa…

This early-phase study tests an experimental drug called ziftomenib in adults with acute myeloid leukemia (AML) who have had a stem cell transplant. The goal is to find a safe dose and see if the drug can help prevent the cancer from coming back. About 22 participants will take t…

This study is for people with certain blood cancers, like leukemia or lymphoma. It tests a stem cell transplant from a half-matched donor, using a special drug combo (treosulfan and fludarabine) plus low-dose radiation to prepare the body. The goal is to see if this approach help…

This study tests whether adding venetoclax to standard chemotherapy before a stem cell transplant can help people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) live longer without their cancer coming back. About 324 adults aged 18 to 70 will receiv…

This study tests a daily pill called enasidenib given after a donor stem cell transplant to people with a specific genetic form of acute myeloid leukemia (IDH2 mutation). The goal is to see if the drug is safe and can help prevent the leukemia from coming back. About 35 participa…

This study compares a new drug, CPX-351, to standard chemotherapy in 248 adults aged 50 and older with newly diagnosed acute myeloid leukemia (AML) that is at intermediate or high risk. The goal is to see if CPX-351 leads to deeper remission with less remaining cancer cells after…

This study tests whether combining two drugs, revumenib and mezigdomide, is safe for people with certain types of acute leukemia that have come back or not responded to treatment. The trial includes about 52 participants aged 12 and older with specific genetic changes in their le…

This study tests whether giving two common heart medicines (a beta blocker and an ACE inhibitor) before and during strong chemotherapy can prevent heart damage in people with newly diagnosed acute myeloid leukemia (AML). About 70 adults will be randomly assigned to receive the he…

This study tests a new drug called Debio 1562M for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The trial has two phases: first, to find a safe dose, and second, to see if the drug can shrink or control the cancer. About 134…

This study tests a radioactive antibody (211At-BC8-B10) given before a donor stem cell transplant for people with high-risk acute leukemias or myelodysplastic syndrome. The antibody seeks out and delivers radiation to cancer cells while sparing healthy cells. The goal is to find …

This study tests whether a maintenance drug (hypomethylating agent) can help people with a favorable type of acute myeloid leukemia (AML) stay in remission longer. About 77 adults who have already achieved remission after initial treatment will receive the drug. The goal is to se…

This early-phase study tests a targeted drug called pemigatinib given after standard chemotherapy for people newly diagnosed with acute myeloid leukemia (AML). The drug blocks a protein (FGFR) that may help leukemia cells grow. The main goal is to find the safest dose and see if …

This early-phase study tests an experimental oral drug, GLB-001, in about 48 adults with acute myeloid leukemia or high-risk myelodysplastic syndromes that returned or didn't respond to prior therapy. The main goals are to find a safe dose and check for side effects. Researchers …

This study tests a new drug combination for adults with a specific type of acute myeloid leukemia (CD123+ AML) who cannot receive standard strong chemotherapy. The treatment adds tagraxofusp to two other drugs (venetoclax and azacitidine) to see if it helps more people achieve co…

This study tests an experimental drug called CTX-712 in adults with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have not responded to or returned after prior treatments. The goal is to find the safest dose and see if the drug can shrink or control the can…

This study tests a combination of four drugs (venetoclax, cladribine, low dose cytarabine, and azacitidine) in adults aged 50 and older with untreated acute myeloid leukemia (AML). The goal is to see if this mix can destroy leukemia cells and lead to remission. Participants will …

This study tests whether adding venetoclax to the standard chemotherapy before a stem cell transplant can help prevent cancer from returning in people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). About 138 participants aged 12 to 60 will be rand…

This study tests whether giving special immune cells (NK cells) before and after a stem cell transplant can help prevent leukemia from coming back in children and young adults (ages 0–25) with acute leukemia that is hard to treat or has leftover disease. The NK cells are grown in…

This study tests a new combination of drugs for people newly diagnosed with a specific type of acute myeloid leukemia (AML). The treatment uses venetoclax, which blocks a protein that helps cancer cells survive, along with three chemotherapy drugs. The goal is to see if this comb…

This early-phase study tests a new drug called HC-7366 in 18 adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goal is to find a safe dose and watch for side effects. Researchers will also see if the drug helps control the disease…

This early-phase study tests whether adding an experimental drug called defactinib to an approved oral treatment (decitabine/cedazuridine) is safe and tolerable for people with high-risk myelodysplastic syndromes, certain acute myeloid leukemias, and chronic myelomonocytic leukem…

This study tests a new treatment for adults with aggressive blood cancers like acute myeloid leukemia (AML) that are hard to cure. Patients receive a combination of chemotherapy drugs (decitabine plus FLAG-Ida) and total body radiation, followed by a stem cell transplant from a h…

This early-phase study tests the safety and best dose of revumenib, a drug that blocks a protein fueling leukemia growth, in 27 adults and children with specific genetic types of acute leukemia. Participants take revumenib after a stem cell transplant to help keep the cancer from…

This study tests a treatment plan for adults aged 60 and older with newly diagnosed, high-risk acute myeloid leukemia (AML) or similar blood cancers. The approach combines strong chemotherapy (FLAG-Ida) with a donor stem cell transplant given just days later, using lower-intensit…

This study looks at how the body handles the cancer drug ASTX727 in people with severe kidney problems compared to those with normal kidneys. About 18 adults with certain blood cancers or solid tumors will take the drug for up to 8 weeks. The goal is to see if the drug is safe an…

This study tests whether using a person's genetic risk can better prevent serious mold infections in patients with acute myeloid leukemia (AML) receiving chemotherapy. About 410 adults will be randomly assigned to different antifungal prevention plans based on their genetic profi…

This study tests whether adding venetoclax to a standard chemotherapy regimen (FLAG IDA) can better eliminate leukemia cells in people newly diagnosed with acute myeloid leukemia (AML). About 102 adults aged 18 to 65 will be randomly assigned to receive either the new combination…

This study tests a daily pill (decitabine) given alone or with other targeted drugs to adults whose acute myeloid leukemia (AML) is in remission. The goal is to see if this maintenance therapy is safe and can help prevent the cancer from returning. About 125 participants will be …

This study is for adults aged 59 and younger with a high-risk form of acute myeloid leukemia (AML) that is harder to treat. It compares the standard chemotherapy with several newer drug combinations to see which works better at shrinking the cancer. The goal is to find a more eff…

This study looks at how the cancer drug ASTX727 works in people with moderate or severe liver problems. It includes 27 adults with certain blood cancers or solid tumors. The goal is to understand how the liver affects the drug's safety and processing in the body.

This early-stage study tests a new drug, BMS-986497, for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The drug is given alone or with standard medicines (azacitidine and venetoclax) to find the safest…

This study tests a new treatment for adults with a specific type of acute myeloid leukemia (FLT3-ITD). The goal is to see if a combination of drugs (gilteritinib, venetoclax, and azacitidine) followed by high-dose chemotherapy can control the disease well enough to avoid a stem c…

This study tests whether combining three drugs—quizartinib, decitabine, and venetoclax—can better control acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome. The trial includes 73 adults aged 60 or older who cannot have standard intensive chemotherapy, or whose ca…

This study tests whether a gentler, low intensity therapy works better than strong chemotherapy for people whose acute myeloid leukemia (AML) has come back or not responded to treatment. About 339 adults with AML in their first or second relapse will be randomly assigned to one o…

This early-phase study tests a new type of immune cell (CIML NK cells) combined with a low-dose drug (IL-2) in people whose leukemia or related blood cancers have returned after a stem cell transplant. The goal is to find a safe dose and see if it can put the cancer back into rem…

This study tests a combination of four drugs (cladribine, idarubicin, cytarabine, and quizartinib) in people with acute myeloid leukemia or high-risk myelodysplastic syndrome that is either newly diagnosed or has returned/not responded to treatment. The goal is to see if this mix…

This early-stage study tests a new treatment for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack a protei…

This study tests a drug called romiplostim N01 to see if it can help platelets recover faster after a stem cell transplant in people with blood cancers like leukemia. About 130 participants will either get the drug or standard care. The goal is to reduce bleeding risk and improve…

This early-phase study tests a new stem cell treatment called Orca-T, combined with targeted radiation and chemotherapy, for people aged 60-75 with acute leukemias or myelodysplastic syndrome (MDS). The goal is to find the safest dose and see how well the body tolerates the treat…

This study tests a refined cord blood transplant method for people with high-risk blood cancers like leukemia and lymphoma. Participants receive chemotherapy and radiation before the transplant to prepare the body, then drugs after to prevent rejection. The goal is to improve sur…

This phase 3 study tests whether adding bleximenib (a drug that blocks a cancer-driving protein interaction) to standard chemotherapy improves outcomes for adults with newly diagnosed acute myeloid leukemia (AML) that has specific genetic changes (KMT2A rearrangement or NPM1 muta…

This study tests a combination of two drugs, cladribine and venetoclax, in adults with a specific type of acute myeloid leukemia (monocytic AML) that came back or didn't get better after standard treatment. The goal is to see how many patients achieve remission or significant blo…

This early-phase study tests a new drug called ziftomenib combined with two other medicines (venetoclax and gemtuzumab) in children and young adults aged 3 to 21 with acute myeloid leukemia that has come back or not responded to treatment. The main goal is to find a safe dose and…

This early-phase trial tests a new treatment for adults with acute myeloid leukemia that has returned or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack leukemia cells. The main goals are to…

This early-stage study tests a new type of stem cell transplant for children whose blood cancers or solid tumors have come back or are hard to treat. Doctors use a special method to remove certain immune cells from the donor's stem cells and give a drug called zoledronate after t…

This early-phase study tests a new treatment called ADCLEC.syn1 CAR T cells for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The main goal is to find a safe dose and check for side effects. About 40 participants will receive th…

This study tests a new daily pill, LP-118, in up to 100 people with blood cancers that have come back or not responded to treatment. The main goal is to find the safest dose and see how the drug works in the body. Early results will also hint at whether it can shrink tumors or sl…

This early-phase study tests a new two-drug combination (bomedemstat plus venetoclax) in 18 adults whose acute myeloid leukemia (AML) has returned or not responded to standard therapy. The main goal is to find a safe dose and understand side effects. Researchers will also check i…

This study tests if a new chemotherapy combination (TmBU) works better than the standard one (mBUCY) before a stem cell transplant for people with high-risk or hard-to-treat acute leukemia. About 48 adults aged 65 or younger will be randomly assigned to one of the two regimens. T…

This early-phase study tests a new treatment for adults with acute myeloid leukemia or myelodysplastic syndrome who still have measurable disease after standard therapy. The treatment uses the patient's own blood cells that are specially armed with a bispecific antibody to target…

This study tests a targeted drug called gemtuzumab ozogamicin in adults with acute myeloid leukemia who are in remission but still have small amounts of cancer cells (measurable residual disease). The drug works like a smart bomb, attaching to a protein on leukemia cells and deli…

This early-stage trial tests an experimental pill called MRX-2843 in teens and adults whose acute leukemia has returned or not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 50 participants will take the pill daily in 2…

This study tests a new drug called CCS1477 (inobrodib) in people with advanced blood cancers like leukemia, lymphoma, and multiple myeloma. The goal is to see if the drug is safe and can help control the disease. About 250 participants who have tried standard treatments without s…

This study tests a new drug called revumenib in people with certain types of leukemia that have come back or not responded to other treatments. The goal is to find the best dose and see if it can help control the disease. About 447 adults with specific genetic changes (MLL/KMT2A …

This study tests a new combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a stem cell transplant for people with intermediate or high-risk acute myeloid leukemia (AML). About 56 adults aged 18-55 who have not had prior leukemia treatment will …

This study tests whether a combination of two drugs, venetoclax and azacitidine, can eliminate small amounts of leukemia cells that remain after initial chemotherapy in people with acute myeloid leukemia (AML). About 29 participants will receive up to 4 treatment cycles before a …

This study tests an oral drug (ASTX030) that combines two chemotherapy agents to treat certain blood cancers like myelodysplastic syndromes and acute myeloid leukemia. It aims to see if taking a pill is as effective as getting injections. About 316 adults will participate over ro…

This early-stage trial tests whether adding decitabine and venetoclax to a standard stem cell transplant is safe for people with high-risk blood cancers like leukemia. About 20 adults aged 18-75 with a matching donor will take part. The goal is to find the best dose that limits s…

This study is for younger adults with a certain type of acute myeloid leukemia (AML) that has an intermediate risk. It tests whether adding the drug venetoclax to standard chemotherapy can clear more cancer cells from the bone marrow than standard treatment alone. About 153 peopl…

This study tests a new drug combination (venetoclax plus other medicines) without traditional strong chemotherapy for adults newly diagnosed with a rare genetic subtype of acute myeloid leukemia. The goal is to see if this gentler approach can achieve complete remission and reduc…

This study tests a combination of four chemotherapy drugs (cladribine, idarubicin, cytarabine, and venetoclax) in people with acute myeloid leukemia, high-risk myelodysplastic syndrome, or a fast-growing form of chronic myeloid leukemia. The goal is to see how well these drugs ki…

This early-stage trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV), a common and dangerous infection after transplant. About 46 people with various blood cancers or disorders will take part. The g…

This study tests a vaccine (CMV-MVA Triplex) given to stem cell donors to help prevent CMV infection in patients receiving a stem cell transplant. The vaccine boosts the donor's immunity against CMV, which is then passed to the patient through the transplant. About 216 donor-reci…

This early-phase study tests whether two metal-removing drugs (edetate calcium disodium and succimer) are safe and can help control acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) when given alongside chemotherapy. About 58 adults with these blood cancers will rece…

This study tests whether tranexamic acid, a drug that helps blood clots stay in place, can safely reduce bleeding in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). About 75 adults receiving less-intensive chemotherapy and having low platelet counts w…

This study looks at whether massage therapy can improve sleep for children and teens (ages 12-21) who are in the hospital for cancer treatment or a stem cell transplant. Researchers will compare sleep minutes and quality between those who get standard care and those who also rece…

This study is testing whether giving blood transfusions at home is practical and acceptable for cancer patients who need regular transfusions. About 30 adults with blood cancers or bone marrow disorders will receive 1-5 blood units at home. Researchers will track how often transf…

This study is for people with acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome (MDS). It aims to develop special lab tests that can find tiny amounts of cancer cells left after treatment, called minimal residual disease. By detecting these cells early, doctors …

This study looks at how the immune system's T-cells change in people with acute myeloid leukemia (AML) after a stem cell transplant. Researchers will analyze blood samples from 250 participants to see if T-cell patterns can predict complications like graft-versus-host disease or …

This study follows people with inherited gene changes (especially in the DDX41 gene) that raise the risk of blood cancers like MDS and AML. Researchers will collect health information, blood, and other samples over 10 years to learn how these gene changes lead to cancer. Particip…

This study looks at how the body absorbs, breaks down, and gets rid of a radioactive form of the drug bleximenib in 10 people with acute leukemia. Participants have a type of leukemia that has come back or not responded to other treatments. The goal is to understand the drug's pa…

This study is testing whether a special type of PET scan called 18F FLT can find signs of leukemia or other blood cancers after treatment. About 60 people aged 4 to 80 with relapsed or hard-to-treat leukemia or myeloma will get the scan before and after therapy. The goal is to se…

This study looks at whether certain proteins in the blood (called cytokines) can help predict how well patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or chronic myelomonocytic leukemia will do on a milder type of chemotherapy (azacytidine). Researchers …

This study looks at whether giving blood transfusions only when hemoglobin drops below 7 gm/dL (instead of 9 gm/dL) is safe and maintains quality of life in adults with acute leukemia or related blood cancers who have had chemotherapy or a stem cell transplant. About 50 participa…

This study collects blood and tissue samples from 2000 people—some with cancer, some without—to help researchers develop and improve blood tests that can detect many types of cancer early. Participants provide samples that are stored and later used to test new diagnostic methods.…

This study looks at whether finding leukemia stem cells in the blood and bone marrow can help predict if a child's leukemia will come back. It involves 283 children with acute myeloid leukemia. The goal is to improve relapse prediction so doctors can treat earlier and more effect…

This study looks at how bone marrow changes in people with acute leukemia after they receive total body irradiation and chemotherapy. Researchers will use special scans and collect blood and bone marrow samples to track these changes over time. The goal is to learn more, not to t…

This study is testing whether special scans (PET/MR, PET/CT, and whole-body MRI) can find leukemia that has spread outside the bone marrow in people newly diagnosed with acute myeloid leukemia (AML). About 77 participants will get these scans to see how often this hidden leukemia…

This study looks at whether a new whole genome test called ChromoSeq can give doctors more detailed genetic information for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) than current tests. Researchers will compare ChromoSeq results to standard geneti…

This study is creating a large database of people in China with various blood diseases, such as leukemia, multiple myeloma, and hemophilia. Researchers will collect information from medical records and follow participants over time to learn about disease patterns, treatments, and…

This study looks at how the drug venetoclax behaves in the bodies of people with acute myeloid leukemia (AML). Researchers will take extra blood samples to measure drug levels and see how they relate to treatment response. About 100 adults starting venetoclax plus azacitidine wil…

This study examines memory, concentration, and language problems caused by chemotherapy in people with acute myeloid leukemia, Hodgkin's lymphoma, or non-Hodgkin's lymphoma. Researchers will compare 120 patients with healthy relatives to measure changes in thinking skills and qua…

This study watches 45 people with neuroendocrine tumors who are getting or have gotten peptide radionuclide therapy (PRRT). Researchers will test blood samples over up to 5 years to find genetic changes that might lead to myelodysplastic syndrome or acute myeloid leukemia. The go…

This study examines stored umbilical cord blood from 300 children who later developed leukemia. Researchers will look for the same genetic mutations found in the children's leukemia cells within their newborn cord blood. The goal is to understand how and when these cancer-causing…

This study tests a telehealth program to help older adults (60+) with blood cancers like leukemia talk with their doctors about their care wishes. It aims to reduce anxiety and improve completion of advance directives. About 207 patients and their caregivers will participate remo…

This study looks at whether providing financial navigation services can reduce the money-related stress (financial toxicity) that often comes with cancer treatment. About 120 adults aged 18-64 with newly diagnosed acute myeloid leukemia (AML) who are starting intensive chemothera…

This study uses artificial intelligence and real-world patient data to compare a new drug combination (venetoclax plus decitabine) against standard chemotherapy for elderly patients (ages 60-75) with acute myeloid leukemia (AML). Researchers will analyze records from nearly 2,000…

This study screens 2,000 adults with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome. Researchers test blood and bone marrow for specific markers to see if participants can join a treatment trial that targets their cancer type. The goal is to make the matching …

This study screens children and young adults (up to age 22) whose leukemia has returned or is difficult to treat. By testing their blood and bone marrow, doctors look for specific genetic markers to match them with the most promising experimental treatments. The goal is to improv…

This study collects blood and bone marrow samples from 80 adults with newly diagnosed acute myeloid leukemia (AML) who are receiving standard treatment with azacitidine and venetoclax. Researchers will analyze the immune profile of these samples to understand how the body respond…